In Vivo Efficacy of Plazomicin Alone or in Combination with Meropenem or Tigecycline against Enterobacteriaceae Isolates Exhibiting Various Resistance Mechanisms in an Immunocompetent Murine Septicemia Model | Zendy

Kamilia Abdelraouf | Zendy; Aryun Kim | Zendy; Kevin M. Krause | Zendy; David P. Nicolau | Zendy

Open Access

In Vivo Efficacy of Plazomicin Alone or in Combination with Meropenem or Tigecycline against Enterobacteriaceae Isolates Exhibiting Various Resistance Mechanisms in an Immunocompetent Murine Septicemia Model

Author(s) -

Kamilia Abdelraouf,

Aryun Kim,

Kevin M. Krause,

David P. Nicolau

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01074-18

Subject(s) - tigecycline , enterobacteriaceae , meropenem , microbiology and biotechnology , in vivo , biology , enterobacteriaceae infections , medicine , drug resistance , antibiotics , antibiotic resistance , escherichia coli , gene , genetics

Plazomicin is a novel aminoglycoside with potentin vitro activity against multidrug- and carbapenem-resistantEnterobacteriaceae . The objective of this study was to assess the efficacy of plazomicin exposure, alone and in combination with meropenem or tigecycline, againstEnterobacteriaceae in the immunocompetent murine septicemia model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research